Cite
MLA Citation
L Tsilika et al.. “P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?.” Thorax, vol. 72, n.d., pp. A126–A127. http://access.bl.uk/ark:/81055/vdc_100137791605.0x00002d